Trial Profile
Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma - MASTER Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jan 2024
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms MASTER Trial
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 19 Nov 2023 Status changed from active, no longer recruiting to completed.
- 17 Jun 2023 Planned End Date changed from 30 Aug 2023 to 30 Sep 2023.